This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Aug 2011

Genentech Sells Clinical Manufacturing Plant to Gilead

The OCP facility is currently produces biologic compounds for toxicological, Phase I and Phase II studies.

Genentech, a member of the Roche Group, has agreed to sell its clinical biologics manufacturing facility and certain process development assets in Oceanside, CA to biopharmaceutical firm Gilead Sciences. The transaction is expected to close in the third quarter, subject to certain conditions.

 

The agreement covers Genentech’s Oceanside Clinical Plant (OCP), a 70,000-sq.-ft. facility and certain process development assets. Gilead will hire approximately 55 Genentech manufacturing specialists and process development scientists familiar with the facilities to assist with operations.

 

The OCP facility is currently produces biologic compounds for toxicological, Phase I and Phase II studies. Initially, Gilead will use the facility for the process development and manufacture of GS 6624 (fo

Related News